We are live on ! Find out more
ATXS

Astria Therapeutics
ATXS

Delisted

ATXS was delisted on the 22nd of January, 2026.

Back to rankings

20 hedge funds and large institutions have $129M invested in Astria Therapeutics in 2015 Q2 according to their latest regulatory filings, with 20 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.

New
Increased
Maintained
Reduced
Closed
Holders
20
Holders Change
+20
Holders Change %
–
% of All Funds
0.54%
Holding in Top 10
2
Holding in Top 10 Change
+2
Holding in Top 10 Change %
% of All Funds
0.05%
New
20
Increased
–
Reduced
–
Closed
–
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
SHI
SV Health Investors
Massachusetts
+$36M
2
CV
Clarus Ventures
Massachusetts
+$34.7M
3
Fidelity Investments
Fidelity Investments
Massachusetts
+$18.3M
4
CCM
Camber Capital Management
Massachusetts
+$11.7M
5
DM
Deerfield Management
New York
+$9.3M

Top Sellers

No sellers this quarter
Name Holding Trade Value Shares
Change 		Change in
Stake
SHI
1
SV Health Investors
Massachusetts
$34.9M +$36M +47,628 New
CV
2
Clarus Ventures
Massachusetts
$33.6M +$34.7M +45,875 New
Fidelity Investments
3
Fidelity Investments
Massachusetts
$17.8M +$18.3M +24,262 New
CCM
4
Camber Capital Management
Massachusetts
$11.3M +$11.7M +15,460 New
DM
5
Deerfield Management
New York
$9.01M +$9.3M +12,301 New
SFM
6
Sphera Funds Management
Israel
$5.06M +$5.62M +7,434 New
Wellington Management Group
7
Wellington Management Group
Massachusetts
$3.73M +$3.84M +5,086 New
RPAM
8
Rhenman & Partners Asset Management
Sweden
$3.24M +$3.34M +4,424 New
BI
9
BVF Inc
California
$2.75M +$2.83M +3,750 New
PI
10
Putnam Investments
Massachusetts
$1.81M +$1.87M +2,469 New
Vanguard Group
11
Vanguard Group
Pennsylvania
$1.07M +$1.11M +1,467 New
MIM
12
Monashee Investment Management
Massachusetts
$977K – – –
Millennium Management
13
Millennium Management
New York
$913K +$943K +1,247 New
Alyeska Investment Group
14
Alyeska Investment Group
Illinois
$611K +$630K +833 New
Federated Hermes
15
Federated Hermes
Pennsylvania
$611K +$630K +833 New
CC
16
Clearline Capital
New York
$571K +$590K +780 New
Norges Bank
17
Norges Bank
Norway
$488K +$504K +667 New
Goldman Sachs
18
Goldman Sachs
New York
$305K +$315K +417 New
FAM
19
Fred Alger Management
New York
$244K +$252K +333 New
Deutsche Bank
20
Deutsche Bank
Germany
$29K +$30.2K +40 New
TRCT
21
Tower Research Capital (TRC)
New York
$8K +$8.31K +11 New

ATXS Hedge Fund Activity: Q2 2015 in Review

20 of the 3,713 institutional investors tracked by Wall St. Rank reported a position in Astria Therapeutics (ATXS) for Q2 2015, worth a combined $129M.

Buyers outnumbered sellers: 20 funds opened new ATXS positions and 0 closed out — a net gain of 20 holders — while 0 added to existing stakes and 0 trimmed.

The largest buyer was SV Health Investors, opening a new position worth an estimated $36M.

  • 20 institutional investors held Astria Therapeutics (ATXS) as of Q2 2015, up from 0 in Q1 2015.
  • Funds reported $129M of Astria Therapeutics stock for Q2 2015.
  • 20 funds opened new Astria Therapeutics positions in Q2 2015 and 0 closed out, a net change of +20 holders.
  • The largest Astria Therapeutics buyer in Q2 2015 was SV Health Investors, an estimated $36M added.

Based on aggregated 13F filings for Q2 2015.